<DOC>
	<DOCNO>NCT02908672</DOCNO>
	<brief_summary>This Phase III , double-blinded , placebo-controlled , randomize , multicenter study design evaluate efficacy , safety , pharmacokinetics combination atezolizumab ( ATZ ) , cobimetinib vemurafenib compare combination ATZ placebo , cobimetinib vemurafenib participant previously untreated BRAFv600 mutation-positive metastatic unresectable locally advanced melanoma .</brief_summary>
	<brief_title>A Study Atezolizumab Plus Cobimetinib Vemurafenib Versus Placebo Plus Cobimetinib Vemurafenib Previously Untreated BRAFv600 Mutation-Positive Participants With Metastatic Unresectable Locally Advanced Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Age great equal ( &gt; /= ) 18 year Females child bear potential male female partner must use contraceptive method failure rate less equal ( &lt; /= ) 1 % per year require treatment 6 month post treatment . Males expose pregnant partner sperm refrain donate sperm 6 month post treatment Histologically confirm Stage IV ( metastatic ) unresectable Stage IIIc ( locally advance ) melanoma Naive prior systemic anticancer therapy melanoma ( example : chemotherapy , hormonal therapy , target therapy , immunotherapy , biologic therapy ) except adjuvant treatment interferon ( IFN ) , interleukin ( IL ) 2 , vaccine therapy herbal therapy Documentation BRAFv600 mutationpositive status melanoma tumor tissue ( archival newly obtain ) use clinical mutation test approve local health authority Eastern Cooperative Oncology Group Performance ( ECOG ) Status 0 1 Measurable disease accord RECIST v1.1 Life expectancy &gt; /=18 week For participant receive therapeutic anticoagulation : International normalized ratio ( INR ) activate partial thromboplastin time ( aPTT ) less equal ( &lt; /= ) 1.5*upper limit normal ( ULN ) within 28 day prior initiation study treatment For participant receive therapeutic anticoagulation : stable anticoagulant regimen stable INR 28 day immediately precede initiation study treatment CancerRelated Major surgical procedure within 4 week prior study treatment initiation Traumatic injury palliative radiotherapy within 2 week prior study treatment initiation Active malignancy ( BRAFv600 mutationpositive melanoma ) malignancy within 3 year prior screen , exception resect melanoma , resect basal cell carcinoma ( BCC ) , resect cutaneous squamous cell carcinoma ( SCC ) , resect carcinoma situ cervix , resect carcinoma situ breast , situ prostate cancer , limitedstage bladder cancer , curatively treated malignancy participant diseasefree least 3 year Ocular History evidence retinal pathology ophthalmologic examination consider risk factor neurosensory retinal detachment , central serous chorioretinopathy , retinal vein occlusion ( RVO ) , neovascular macular degeneration Cardiac History clinically significant cardiac dysfunction Left ventricular ejection fraction ( LVEF ) institutional low limit normal 50 % Central Nervous System ( CNS ) Untreated actively progress CNS lesion ( carcinomatous meningitis ) History metastasis brain stem , midbrain , pons , medulla , within 10 millimeter ( mm ) optic apparatus ( optic nerve chiasm ) ; leptomeningeal metastatic disease ; intracranial hemorrhage Additional Current severe , uncontrolled systemic disease ( include , limited , clinically significant cardiovascular , pulmonary , renal disease ) cancer History malabsorption clinically significant metabolic dysfunction Pregnant breastfeeding , intend become pregnant study Prior allogeneic stem cell solid organ transplantation History idiopathic pulmonary fibrosis , organize pneumonia ( example : bronchiolitis obliterans ) , druginduced pneumonitis , idiopathic pneumonitis , evidence active pneumonitis screen chest compute tomography ( CT ) scan History autoimmune disease Known clinically significant liver disease , inherit liver disease active viral disease Active tuberculosis Treatment therapeutic oral intravenous ( IV ) antibiotic ; live , attenuate vaccine ; systemic immunosuppressive medication Known hypersensitivity biopharmaceutical agent produce Chinese hamster ovary cell component atezolizumab , cobimetinib , vemurafenib formulation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>